



## **Nexstim Receives NBS 6 System Order from New Research Customer**

*Press release, Helsinki, 20 November 2025 at 9 AM (EET)*

Nexstim Plc (“Nexstim” or the “Company”) has received an order from a new U.S.-based customer for an NBS 6 system intended for neuroscience EEG research. The system will be used to non-invasively measure objective brain responses in studies exploring future clinical applications outside of Alzheimer’s disease.

This system is the latest version of the NBS 6 system built on Nexstim's unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology, with a modular system concept that allows system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests. The NBS 6 is FDA-cleared for the pre-procedural mapping of the speech and motor cortices of the brain and for the treatment of major depressive disorder (MDD).

**Mikko Karvinen**, CEO of Nexstim, comments: *“Earlier this year we started reporting on our Research and Neuroscience business, it having been an increasingly important part of our strategy and operations. We are happy to be able to offer the best tools for research studies and already have a large, established research network that I warmly welcome this new customer to join.”*

**Further information is available on the website [www.nexstim.com](http://www.nexstim.com), or by contacting:**

**Mikko Karvinen**, CEO

+358 50 326 4101

[mikko.karvinen@nexstim.com](mailto:mikko.karvinen@nexstim.com)

### **About Nexstim Plc**

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit [www.nexstim.com](http://www.nexstim.com)